SOLID BIOSCIENCES INC (SLDB)
US83422E2046 - Common Stock
SOLID BIOSCIENCES INC
NASDAQ:SLDB (1/8/2025, 8:00:01 PM)
After market: 4.01 -0.02 (-0.5%)4.03
+0.11 (+2.81%)
Company Profile
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The firm also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. The company also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Company Info
SOLID BIOSCIENCES INC
500 Rutherford Avenue, 3rd Floor
Charlestown MASSACHUSETTS 02139
P: 16173374680
CEO: Ilan Ganot
Employees: 88
Website: https://www.solidbio.com/
SLDB News
19 hours ago - Solid Biosciences Inc.Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceCHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company...
2 days ago - ChartmillWhat's going on in today's after hours sessionThese stocks are moving in today's after hours session
2 days ago - Solid Biosciences Inc.Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich’s ataxia - - Dual...
17 days ago - Solid Biosciences Inc.Solid Biosciences Added to the Nasdaq Biotechnology IndexCHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company...
a month ago - Solid Biosciences Inc.Solid Biosciences to Participate at Upcoming Investor ConferencesCHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company...
2 months ago - Solid Biosciences Inc.Solid Biosciences to Present at the Jefferies London Healthcare ConferenceCHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company...
SLDB Twits
Here you can normally see the latest stock twits on SLDB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
